Pharmstandard
 | |
| Public (OAO) | |
| Traded as |
MCX: PHST LSE: PHST |
| Industry | Pharmaceuticals |
| Founded | 2003 |
| Headquarters | Dolgoprudny, Russia |
Key people |
Viktor Vladimirovich Kharitonin,(Chairman) Igor Konstantinovich Krylov, (CEO) |
| Products | Remedies |
| Revenue |
 US$ 1.6 billion (2012) |
| Profit |
US$ 321.1 million (2012) |
Number of employees | 5,001 |
| Website | pharmstd.com |
Pharmstandard is the leading Russian pharmaceutical company, it is headquartered in Dolgoprudny.
Pharmstandard portfolio includes over 200 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer, etc. Over 90 products offered by Pharmstandard are included in the List of Vital Pharmaceutical Products.[1]
The company has six manufacturing facilities located in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk and Tyumen.
References
| |
|
This article is issued from Wikipedia - version of the 10/22/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.